EBS Q3 2023 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$271M+12.8% YoY

Gross Profit

$92M34.2% margin

Operating Income

-$242M-89.5% margin

Net Income

-$263M-97.4% margin

EPS (Diluted)

$-5.13

QoQ Revenue Growth

-19.9%

Cash Flow

Operating Cash Flow

$60M

Free Cash Flow

$47M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$1.2B

Stockholders' Equity

$697M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$271M	$240M	+12.8%
Gross Profit	$92M	$51M	+80.8%
Operating Income	-$242M	-$45M	-434.4%
Net Income	-$263M	-$87M	-202.4%

Revenue Segments

Product

$250M92%

Contract Development And Manufacturing

$14M5%

Contracts and Grants

$7M2%

Geographic Segments

Services Segment

$14M100%